Results 51 to 60 of about 23,497 (215)

Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. [PDF]

PLoS ONE, 2014
There are few data on the prevalence of WHO transmitted drug resistance mutations (TDRs) that could affect treatment responses to first line antiretroviral therapy (ART) in Hunan Province, China.Determine the prevalence of WHO NRTI/NNRTI/PI TDRs in ART ...
Zou Xiaobai, Chen Xi, Hongping Tian, Ann B Williams, Honghong Wang, Jianmei He, Jun Zhen, Jennifer Chiarella, Lisebeth A Blake, Gregory Turenchalk, Michael J Kozal   +10 more
doaj   +1 more source

Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: Comparison with dual X-ray absorptiometry [PDF]

, 2016
Objectives: With the development of effective treatments and the resulting increase in life expectancy, bone mineral density (BMD) alteration has emerged as an important comorbidity in human immunodeficiency virus type-1 (HIV-1)-infected individuals. The
Cacciatore, Francesco, Ceci, Fabrizio, FANTAUZZI, Alessandra, Floridia, Marco, MEZZAROMA, Ivano, VULLO, Vincenzo   +5 more
core   +3 more sources

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine

Viruses
Introduction: Few data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV). Methods:
Pavithra Nagarajan, Jinru Zhou, Giulia Di Teodoro, Francesca Incardona, Carole Seguin-Devaux, Rolf Kaiser, Ana B. Abecasis, Perpetua Gomes, Kaiming Tao, Maurizio Zazzi, Robert W. Shafer   +10 more
doaj   +1 more source

Long‐term effectiveness of initiating non‐nucleoside reverse transcriptase inhibitor‐ versus ritonavir‐boosted protease inhibitor‐based antiretroviral therapy: implications for first‐line therapy choice in resource‐limited settings

Journal of the International AIDS Society, 2016
Introduction In many resource‐limited settings, combination antiretroviral therapy (cART) failure is diagnosed clinically or immunologically. As such, there is a high likelihood that patients may stay on a virologically failing regimen for a substantial ...
Viviane D Lima, Mark Hull, David McVea, William Chau, P Richard Harrigan, Julio SG Montaner   +5 more
doaj   +1 more source

Evolution of primary HIV drug resistance in a subtype C dominated epidemic in Mozambique. [PDF]

PLoS ONE, 2013
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by decentralization and expansion, resulting in a more than 20-fold increase in coverage by 2009. Implementation of HIV drug resistance threshold surveys (HIVDR-
Dulce Celina Adolfo Bila, Peter Young, Harriet Merks, Adolfo Salvador Vubil, Mussagy Mahomed, Angelo Augusto, Celina Monteiro Abreu, Nédio Jonas Mabunda, James I Brooks, Amilcar Tanuri, Ilesh Vinodrai Jani   +10 more
doaj   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Nevirapine Use to Reduce Mother-To-Child Transmission of HIV in Canada

Canadian Journal of Infectious Diseases, 2001
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is used to treat adults and children with human immunodeficiency virus (HIV) infection.
Committee for Canadian Paediatric AIDS Research Group
doaj   +1 more source

Genetic mechanisms of resistance to NRTI and NNRTI [PDF]

HIV Clinical Trials, 2002
Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) seems to develop following three different pathways. Discriminatory mutations favor the binding of physiologic nucleosides over that of drugs. The newly so-called nucleoside-associated mutations (NAMs) enhance the removal of chain terminators (pyrophosphorolysis) from the cDNA in ...
Vincent, Soriano, Carmen, de Mendoza
openaire   +2 more sources

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source